Drug Shortage Report for LEVOTHYROXINE SODIUM INJECTION
| Report ID | 239468 |
| Drug Identification Number | 02499924 |
| Brand name | LEVOTHYROXINE SODIUM INJECTION |
| Common or Proper name | LEVOTHYROXINE SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | LEVOTHYROXINE SODIUM |
| Strength(s) | 100MCG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 5 mL |
| ATC code | H03AA |
| ATC description | THYROID PREPARATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-10-31 |
| Actual start date | |
| Estimated end date | 2025-01-15 |
| Actual end date | 2024-11-19 |
| Shortage status | Resolved |
| Updated date | 2024-11-20 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 100 mcg / mL SD Vial 5 mL effective October 31, 2024, until January 15, 2025. As previously communicated, please note that all current inventory is short-dated and expiring October 31, 2024. During this time, our Levothyroxine Sodium for Injection 500 μg SD Vial 10 mL is available as a substitute. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2024-11-20 | French | Compare |
| v4 | 2024-11-20 | English | Compare |
| v3 | 2024-11-01 | English | Compare |
| v2 | 2024-10-04 | French | Compare |
| v1 | 2024-10-04 | English | Compare |
Showing 1 to 5 of 5